Subscribe
shutterstock_1396957739_pavel_kapysh
Pavel Kapysh / Shutterstock.com
4 February 2020AmericasSarah Morgan

Idenix $2.5bn ruling will impede innovation, says Amgen

Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

More on this story

Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC